Avadel Pharmaceuticals shareholders have approved the proposed acquisition by Alkermes plc. At meetings held earlier today, Avadel shareholders voted in favor of Alkermes acquiring the entire issued and to be issued ordinary share capital of the company. The resolutions related to the transaction received strong support, with 97.41% of votes cast in favor at the scheme meeting. Additionally, Avadel shareholders approved, on a non-binding, advisory basis, the specified compensatory arrangements for the company’s named executive officers in connection with the transaction.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Avadel Pharmaceuticals plc published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 9624170) on January 12, 2026, and is solely responsible for the information contained therein.